Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (241-250 of 755) with videos related to

Pageof 76
Sort By:
Arthritis and Rheumatism|March 1, 1993
Antirheumatic drugs: a proposed new classificationJ P Edmonds, D L Scott, D E Furst, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 30, 2008
Oral cyclophosphamide for active scleroderma lung disease: a decision analysisDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Muscle & Nerve|September 19, 2012
Medical costs and health-care resource use in patients with inflammatory myopathies in an insured populationDaniel E Furst, Anthony A Amato, Serban R Iorga, et al.
Rheumatology (Oxford, England)|July 23, 2015
Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapyDaniel E Furst, Arthur Kavanaugh, Stefan Florentinus, et al.
Drug Safety|November 8, 2019
Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World UseChristian M Stach, Victor S Sloan, Thasia G Woodworth, et al.
Rheumatology (Oxford, England)|October 10, 2017
Points to consider when doing a trial primarily involving the heartYannick Allanore, Oliver Distler, Ulrich A Walker, et al.
Rheumatology (Oxford, England)|October 10, 2017
Interstitial lung disease points to consider for clinical trials in systemic sclerosisDinesh Khanna, James Seibold, Jonathan Goldin, et al.
Seminars in Arthritis and Rheumatism|July 9, 2019
Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritisNeta Cohen, Ronnie Gur Lavie, Ya'ara Manor, et al.
Journal of Pharmaceutical Sciences|September 1, 1981
Formation of methyl ester of salicyluric acid during quantitation of salicyluric acid in urine by high-pressure liquid chromatographyR O Day, S H Dromgoole, D E Furst, et al.
The Journal of Rheumatology. Supplement|July 1, 1982
Single dose pharmacokinetics of auranofin in rheumatoid arthritisK Blocka, D E Furst, E Landaw, et al.
Pageof 76

Showing results (241-250 of 755) with videos related to

Sort By:
Pageof 76
Arthritis and Rheumatism|March 1, 1993
Antirheumatic drugs: a proposed new classificationJ P Edmonds, D L Scott, D E Furst, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 30, 2008
Oral cyclophosphamide for active scleroderma lung disease: a decision analysisDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Muscle & Nerve|September 19, 2012
Medical costs and health-care resource use in patients with inflammatory myopathies in an insured populationDaniel E Furst, Anthony A Amato, Serban R Iorga, et al.
Rheumatology (Oxford, England)|July 23, 2015
Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapyDaniel E Furst, Arthur Kavanaugh, Stefan Florentinus, et al.
Drug Safety|November 8, 2019
Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World UseChristian M Stach, Victor S Sloan, Thasia G Woodworth, et al.
Rheumatology (Oxford, England)|October 10, 2017
Points to consider when doing a trial primarily involving the heartYannick Allanore, Oliver Distler, Ulrich A Walker, et al.
Rheumatology (Oxford, England)|October 10, 2017
Interstitial lung disease points to consider for clinical trials in systemic sclerosisDinesh Khanna, James Seibold, Jonathan Goldin, et al.
Seminars in Arthritis and Rheumatism|July 9, 2019
Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritisNeta Cohen, Ronnie Gur Lavie, Ya'ara Manor, et al.
Journal of Pharmaceutical Sciences|September 1, 1981
Formation of methyl ester of salicyluric acid during quantitation of salicyluric acid in urine by high-pressure liquid chromatographyR O Day, S H Dromgoole, D E Furst, et al.
The Journal of Rheumatology. Supplement|July 1, 1982
Single dose pharmacokinetics of auranofin in rheumatoid arthritisK Blocka, D E Furst, E Landaw, et al.
Pageof 76